Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

By N. Rohwer, T. Cramer. Drug resistance updates, 2011

619 citations recorded by the source corpus.

Subfields: Cancer Research, Epidemiology, Oncology

View Paper: https://www.semanticscholar.org/paper/62bc7478b298a093bc7a499bdf3640b182549be7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. S. Påhlman
2. C. Wigerup
3. D. Bexell
4. Abdel Kareem Azab
5. F. Azab
6. Barbara Muz
7. Pilar de la Puente
8. T. Cramer

In Epidemiology

1. G. Semenza
2. Joshua D. Rabinowitz

In Oncology

1. G. Semenza
2. P. Vaupel

Citations in the corpus

• The return of metabolism: biochemistry and physiology of the pentose phosphate pathway (2014, background): “This work supports the notion of HIF-1 as a pivotal mediator of therapy failure and points towards HIF-1-dependent control of cellular metabolism as an important molecular mechanism (Rohwer & Cramer, 2011).”
• Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. (2016, background): “For a comprehensive review of the mechanisms underlying HIF-induced chemotherapeutic resistance, we refer the reader to Rohwer and Cramer (2011).”
• The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy (2015, background): “and senescence of cells, iii) controlling autophagy, p53, and mitochondrial activity.(94,97) Apart from cellular adaptations”
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “Furthermore, cell cycle arrest and compensatory angiogenesis initiated by hypoxia are among the pivotal causes of drug resistance in chemotherapy and anti-angiogenic treatment, respectively.(256,257) HIF-1α is a crucial target for anti-tumor therapy, while some progress has been made in developing n”
• Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy (2012, background): “In addition to extensive data indicating that HIFs mediate resistance to radiation therapy [28] and chemotherapy [29], there is mounting evidence that HIF-1 activity may contribute to the development of resistance to novel targeted therapies, such as imatinib treatment of chronic myeloid leukemia [4”
• Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies (2024, background): “228 – 230 HIFs seem to play a dual role in modulating ferroptosis and subsequently affecting therapeutic ef fi cacy in cancers (Fig.”